Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
…, C Guillemet, M Rios, O Collard, L Bozec… - The lancet …, 2016 - thelancet.com
Background Regorafenib is a multikinase inhibitor with proven activity in refractory
gastrointestinal stromal tumours and chemotherapy-refractory advanced colorectal cancers. We …
gastrointestinal stromal tumours and chemotherapy-refractory advanced colorectal cancers. We …
[HTML][HTML] COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
…, E Laas, Y Kirova, L Cabel, JY Pierga, L Bozec… - Breast Cancer …, 2020 - Springer
Background Cancer patients have been reported to be at higher risk of COVID-19 complications
and deaths. We report the characteristics and outcome of patients diagnosed with …
and deaths. We report the characteristics and outcome of patients diagnosed with …
Characteristics and outcome of SARS-CoV-2 infection in cancer patients
…, X Paoletti, L Bozec… - JNCI cancer …, 2021 - academic.oup.com
Background Concerns have emerged about the higher risk of fatal coronavirus disease 2019
(COVID-19) in cancer patients. In this article, we review the experience of a comprehensive …
(COVID-19) in cancer patients. In this article, we review the experience of a comprehensive …
Interactions between glioma and pregnancy: insight from a 52-case multicenter series
…, T Lesimple, L Bauchet, M Lopes, L Bozec… - Journal of …, 2017 - thejns.org
OBJECTIVE The goal of this study was to provide insight into the influence of gliomas on
gestational outcomes, the impact of pregnancy on gliomas, and the identification of patients at …
gestational outcomes, the impact of pregnancy on gliomas, and the identification of patients at …
Effect of adding docetaxel to androgen-deprivation therapy in patients with high-risk prostate cancer with rising prostate-specific antigen levels after primary local …
…, G Deplanque, D Zylberait, L Bozec… - JAMA …, 2019 - jamanetwork.com
Importance Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in
hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-…
hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-…
[HTML][HTML] Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a …
…, C Sire, E Blot, P Debourdeau, L Bozec… - The Lancet Healthy …, 2024 - thelancet.com
Background At present, there is no established standard treatment for frail older patients with
recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the …
recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the …
Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer
…, S Novello, T Nakamura, AM Liepa, L Bozec… - Clinical cancer …, 2004 - AACR
Purpose: Cisplatin is one of the most active agents for the treatment of non-small cell lung
cancer (NSCLC). It is also known for significant toxicity, which makes it unsuitable for certain …
cancer (NSCLC). It is also known for significant toxicity, which makes it unsuitable for certain …
[HTML][HTML] Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a …
…, E Blot, P Guillet, J Pavillet, L Bozec… - The Lancet Healthy …, 2024 - thelancet.com
Background A standard treatment for fit, older patients with recurrent or metastatic head and
neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME …
neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME …
Primary and secondary breast angiosarcoma: FDG PET/CT series
…, L Champion, L Bozec, V Laurence… - Clinical nuclear …, 2019 - journals.lww.com
Breast angiosarcoma is a rare and aggressive tumor. The role of 18 F-FDG PET/CT in
breast angiosarcoma is poorly known. We report a series of 13 lesions in 11 patients with …
breast angiosarcoma is poorly known. We report a series of 13 lesions in 11 patients with …
[HTML][HTML] Efficacy and safety of combined brain stereotactic radiotherapy and immune checkpoint inhibitors in non-small-cell lung cancer with brain metastases
…, T Frederic-Moreau, MA Massiani, L Bozec… - Biomedicines, 2022 - mdpi.com
Background: To analyze the outcomes of patients with brain metastases (BM) from non-small
cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (…
cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (…
